Linezolid 2 mg/ ml solution for infusion

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

Linezolid

Available from:

Fresenius Kabi Deutschland GmbH

ATC code:

J01XX; J01XX08

INN (International Name):

Linezolid

Dosage:

2 milligram(s)/millilitre

Pharmaceutical form:

Solution for infusion

Prescription type:

Product subject to prescription which may not be renewed (A)

Therapeutic area:

Other antibacterials; linezolid

Authorization status:

Marketed

Authorization date:

2014-12-05

Patient Information leaflet

_Linezolid 2mg/ml FFX & KP– Package leaflet – V004 _
Package leaflet: Information for the use
LINEZOLID 2 MG/ML SOLUTION FOR INFUSION
Linezolid
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT
CONTAINS IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or nurse.
-
If you get any side effects, talk to your doctor or nurse. This
includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1. What Linezolid is and what it is used for
2. What you need to know before you use Linezolid
3. How to use Linezolid
4. Possible side effects
5. How to store Linezolid
6. Contents of the pack and other information
1. WHAT LINEZOLID IS AND WHAT IT IS USED FOR
Linezolid is an antibiotic of the oxazolidinones group that works by
stopping the growth
of certain bacteria (germs) that cause infections. It is used to treat
pneumonia and some
infections in the skin or under the skin. Your doctor will have
decided if Linezolid is
suitable to treat your infection.
2. WHAT YOU NEED TO KNOW BEFORE YOU USE LINEZOLID
YOU SHOULD NOT BE TREATED WITH LINEZOLID
:
•
if you are allergic to linezolid or any of the other ingredients of
this medicine (listed
in section 6).
•
if you are taking or have taken within the last 2 weeks any medicines
known as
monoamine
oxidase
inhibitors
(MAOIs:
for
example
phenelzine,
isocarboxazid,
selegiline, moclobemide). These medications may be used to treat
depression or
Parkinson’s disease;
•
if you are breast-feeding. This is because Linezolid passes into
breast milk and could
affect the baby.
WARNINGS AND PRECAUTIONS
Talk to your doctor, pharmacist or nurse before taking Linezolid.
Linezolid may not be suitable for you if you answer
YES
to any of the following questions.
In this case tell your doctor as he/she will need to check your
general health and your
_Linezolid 2mg/ml FFX & KP– Package leaflet – V004 _
blood pressure before and during y

Summary of Product characteristics

Health Products Regulatory Authority
03 November 2023
CRN008TK0
Page 1 of 15
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Linezolid 2 mg/ ml solution for infusion
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
1 ml solution for infusion contains 2 mg linezolid.
Each 300 ml infusion bag contain 600 mg linezolid.
Excipients: each 300 ml also contains 13.7 g glucose and 114 mg
sodium.
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Solution for infusion
Isotonic, clear, practically free from particles, colourless to yellow
solution.
pH: 4.4-5.2
Osmolality: 270-330 mOsmol/kg
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Nosocomial pneumonia
Community acquired pneumonia
Linezolid is indicated in adults for the treatment of community
acquired pneumonia and nosocomial pneumonia when known
or suspected to be caused by susceptible Gram positive bacteria. In
determining whether Linezolid is an appropriate treatment,
the results of microbiological tests or information on the prevalence
of resistance to antibacterial agents among Gram positive
bacteria should be taken into consideration. (See section 5.1 for the
appropriate organisms).
Linezolid is not active against infections caused by Gram negative
pathogens. Specific therapy against Gram negative
organisms must be initiated concomitantly if a Gram negative pathogen
is documented or suspected.
Complicated skin and soft tissue infections (see section 4.4).
Linezolid is indicated in adults for the treatment of complicated skin
and soft tissue infections ONLY when microbiological
testing has established that the infection is known to be caused by
susceptible Gram positive bacteria.
Linezolid is not active against infections caused by Gram negative
pathogens. Linezolid should only be used in patients with
complicated skin and soft tissue infections with known or possible
co-infection with Gram negative organisms if there are
no alternative treatment options available (see section 4.4). In these
circumstances treatment against Gra